Enhabit (NYSE:EHAB) Lifted to “Hold” at Leerink Partnrs

Leerink Partnrs upgraded shares of Enhabit (NYSE:EHAB) from a strong sell rating to a hold rating in a research note released on Tuesday morning, Zacks.com reports. Leerink Partnrs also issued estimates for Enhabit’s Q3 2024 earnings at $0.04 EPS, FY2024 earnings at $0.20 EPS, Q1 2025 earnings at $0.04 EPS, Q2 2025 earnings at $0.00 EPS, Q3 2025 earnings at $0.03 EPS, FY2025 earnings at $0.12 EPS, FY2026 earnings at $0.05 EPS and FY2027 earnings at ($0.09) EPS.

A number of other brokerages have also commented on EHAB. Jefferies Financial Group lowered Enhabit from a buy rating to a hold rating and dropped their target price for the company from $14.00 to $8.75 in a research report on Thursday, May 9th. Oppenheimer reiterated a market perform rating on shares of Enhabit in a research note on Thursday, March 7th. UBS Group upgraded shares of Enhabit from a sell rating to a neutral rating and set a $9.50 target price for the company in a research report on Thursday, March 7th. Finally, SVB Leerink raised Enhabit from an underperform rating to a market perform rating and set a $8.50 price target on the stock in a research report on Tuesday. One analyst has rated the stock with a sell rating and seven have issued a hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of Hold and an average target price of $10.13.

Enhabit Stock Performance

Enhabit stock remained flat at $8.35 during midday trading on Tuesday. The company’s stock had a trading volume of 309,001 shares, compared to its average volume of 594,033. Enhabit has a 52 week low of $7.12 and a 52 week high of $14.59. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.50 and a current ratio of 1.50. The stock’s 50-day simple moving average is $10.38 and its 200-day simple moving average is $10.05.

Enhabit (NYSE:EHAB) last posted its quarterly earnings results on Wednesday, March 6th. The company reported $0.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.02 by $0.01. Enhabit had a negative net margin of 7.95% and a positive return on equity of 1.43%. The business had revenue of $260.60 million during the quarter, compared to analysts’ expectations of $260.30 million. During the same quarter last year, the company posted $0.32 earnings per share. On average, research analysts anticipate that Enhabit will post 0.24 EPS for the current fiscal year.

Insider Activity at Enhabit

In other news, Director Jeffrey Bolton bought 10,000 shares of the stock in a transaction dated Friday, May 10th. The shares were acquired at an average cost of $8.24 per share, with a total value of $82,400.00. Following the purchase, the director now directly owns 42,299 shares in the company, valued at approximately $348,543.76. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 1.90% of the stock is owned by company insiders.

Institutional Trading of Enhabit

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Gladius Capital Management LP acquired a new stake in Enhabit in the 4th quarter valued at $42,000. Allspring Global Investments Holdings LLC purchased a new position in Enhabit during the first quarter valued at $44,000. Quantbot Technologies LP acquired a new stake in shares of Enhabit in the third quarter valued at about $73,000. ProShare Advisors LLC purchased a new stake in shares of Enhabit during the first quarter worth about $118,000. Finally, Family Firm Inc. acquired a new position in shares of Enhabit during the 1st quarter worth about $124,000.

Enhabit Company Profile

Enhabit, Inc provides home health and hospice services in the United States. Its home health services include patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery, or injury and respiratory diseases; and physical, occupational and speech therapists provide therapy services.